← Back to Calendar

Arvinas Q1 2026 Earnings

Arvinas / Pfizer · $ARVN
Standard Review Earnings
Catalyst Date
May 7, 2026
Time Remaining
37 days
Review Type
Standard (10 mo)

Live Company Data NMS

Updated just now · Data: FMP
Current Price
$10.18 +34.12%
+$2.59 today
Day: $10.00 – $10.33
Market Cap
N/A
52-Week Range
$5.90
$14.51
Current price is at 50% of 52-week range
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.

Indication

Q1 2026 earnings + vepdegestrant PDUFA June 5 preparation update

Key Notes

Q1 2026 earnings expected ~May 7, 2026. Critical update ahead of June 5 vepdegestrant PDUFA date — commercial readiness, Pfizer partnership dynamics, label expectations. Also expected: update on ARV-766 (PROTAC AR degrader) for prostate cancer and broader pipeline.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar